25 Result(s)
-
Article
Kutane Nebenwirkungen onkologischer Systemtherapien
Bestimmte medikamentöse Tumortherapien verursachen kutane Toxizität an Händen, Füßen und Nägeln.
-
Article
Open AccessAnti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization
Topical tirbanibulin is a highly effective and well tolerated novel treatment option for actinic keratoses (AKs). This study aimed to characterize the mode of action of tirbanibulin in keratinocytes (NHEK) and...
-
Article
Fokale dermale Hypoplasie durch pathogene Variante im PORCN-Gen in postzygotischer, unilateraler Mosaik-Konstellation
Wir berichten über eine 29-jährige Patientin mit ab dem Grundschulalter bemerkbaren diskreten zum Teil erythematösen, zum Teil hyperpigmentierten Streifen entlang der Blaschko-Linien an der rechten Körperhälft...
-
Article
Kutane Nebenwirkungen onkologischer Systemtherapien
Bestimmte medikamentöse Tumortherapien verursachen kutane Toxizität an Händen, Füßen und Nägeln.
-
Article
Open AccessPreferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Adjuvant treatment with immune checkpoint inhibitors, such as PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT), has shown a significant improvement in disease-fr...
-
Article
Open AccessHealth-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC...
-
Article
Open AccessLiver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on th...
-
Article
Medikamentöse Therapie des inoperablen Melanoms
Etablierte Therapieverfahren für das inoperable Melanom sind die Immuncheckpointinhibition mit Inhibitoren von CTLA‑4 („cytotoxic T‑lymphocyte-associated protein 4“), PD‑1 („programmed cell death protein 1“) u...
-
Article
Situation klinischer Studien in Deutschland – ein interdisziplinäres Positionspapier
-
Article
Open AccessKey Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
Sonidegib is approved to treat locally advanced basal cell carcinoma (laBCC) in the USA, EU, Switzerland, and Australia and metastatic basal cell carcinoma (mBCC) in Switzerland and Australia in patients not a...
-
Article
Open AccessPatterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
Uveal melanoma (UM) is an orphan cancer of high unmet medical need. Current patterns of care and surveillance remain unclear as they are situated in an interdisciplinary setting.
-
Article
Vorgehen beim Basalzellkarzinom
Das Basalzellkarzinom ist der häufigste Tumor des hellhäutigen Menschen.
-
Article
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
PD-1 inhibition (PD-1i) is the standard of care in melanoma and other malignancies. In patients with bone metastases of solid tumors, the monoclonal antibody denosumab directed against RANKL is approved for th...
-
Article
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma
Globally, basal cell carcinoma is the most commonly diagnosed cancer. While most cases are amenable to surgery, treatment options for advanced basal cell carcinoma, including locally advanced basal cell carcin...
-
Article
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong overall survival (OS) in patients with advanced B-Raf proto-oncogen...
-
Article
Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe
Talimogene laherparepvec, a herpes simplex virus type 1-based intrale-sional oncolytic immunotherapy, is approved in Europe for the treatment of adults with unresectable stage IIIB-IVM1a melanoma, with no bone...
-
Article
Malignes Melanom − Früherkennung, Diagnostik und Nachsorge
Das maligne Melanom ist eine häufige Hautkrebsart mit einer sehr hohen Mortalität. In Europa versterben jährlich etwa 22.000 Menschen daran, davon etwa 2700 Patienten alleine in Deutschland. Die Inzidenz zeigt...
-
Article
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only ...
-
Article
Open AccessTreatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study
Aviscumine, a recombinant plant protein, is an immune modulator that induces ribotoxic stress at the 28S ribosomal RNA subunit. In this way cytokine release and T-cell responses are enhanced. This phase II tri...
-
Article
The Role of the Histamine H4 Receptor in Atopic Dermatitis
The pathology of atopic dermatitis is orchestrated on the cellular level by several different cell types in the characteristic skin lesions. In such lesions, histamine as a mediator of many biological function...
